| Bioactivity | Tyrosinase-IN-13 (compound 3c), a derivative of Flurbiprofen (HY-10582), is a potent, non-competitive tyrosinase inhibitor (IC50=68 μM; Ki=36.3 μM). Tyrosinase-IN-13 is cytotoxic against hepatocellular carcinoma (HepG2), colorectal cancer (HT-29), and melanoma (B16F10)[1]. |
| Target | IC50: 68 μM (Tyrosinase) |
| Name | Tyrosinase-IN-13 |
| Formula | C23H18ClFN4OS |
| Molar Mass | 452.93 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zengin Kurt B, et al. Synthesis of flurbiprofen thiadiazole urea derivatives and assessment of biological activities and molecular docking studies. Chem Biol Drug Des. 2023 Aug 31.. . |